The Long Run with Luke Timmerman

Tim Mayleben, CEO of Esperion Therapeutics, on cholesterol-lowering meds.

David Baker, University of Washington protein designer.

Jigar Raythatha of Constellation Pharma on epigenetic drug development.

John Alam on Alzheimer's drug development.

Tim Springer of Harvard Medical School on his career in science and biotech.

Discussion on the new Henri Termeer biography.

CEO of Synlogic on developing synthetic biology-based drugs.

MIT biologist Phil Sharp on his early career.

Bruce Carter on developing a new tuberculosis drug.

Ted Love of Global Blood Therapeutics on a new drug for sickle cell disease

Joel Marcus, chairman of Alexandria Real Estate Equities, on building in biotech clusters.

Janelle Anderson on venture capital and off-the-shelf cell therapy at Century Therapeutics

Cindy Perettie of Foundation Medicine on genomic analysis for cancer.

Laura Shawver on synthetic biology engineering of cancer drugs.

Liz O'Day on metabolite signatures for predicting cancer drug response.

Jay Bradner, president of Novartis Institutes for Biomedical Research, on his journey from open biology advocate to pharma leadership.

Sheila Gujrathi, CEO of Gossamer Bio, immunologic drug developer

Sage Therapeutics CEO on psychiatric drug development.

Carolyn Bertozzi on becoming a chemical biologist/glycobiologist.

MIT's Bob Langer on his journey in science and entrepreneurship.

Serge Saxonov on the single-cell analysis revolution.

Julia Owens on pivoting, more than once, in a biotech startup.

The co-founders of Adaptive Biotechnologies on immune sequencing.

Bonnie Anderson of Veracyte on genomic diagnostics.

George Scangos on building an infectious disease company

Karen Akinsanya of Schrodinger on computational drug discovery

Ron Renaud on developing messenger RNA therapies.

Krishna Yeshwant of GV on life at the intersection of tech and biotech.

Ned David on extending human healthspan.

Julie Sunderland on VC investing at the nexus of tech and biotech.

Barbara Weber on synthetic lethal cancer drug discovery

John Wilbanks on making it easy to share biological data.

Sabah Oney on becoming a scientific business executive.

Amy Abernethy on making EHRs useful for drug development.

Meg Tirrell on covering biotech on TV.

Thong Le on building startups to suit pharma needs.

Ankit Mahadevia on the antibiotic opportunity

Chris Garabedian on the "middle market" of biotech VC.

Vicki Sato on her career in biotech.

Tony Coles on neurodegenerative drug discovery and inclusive leadership.

Ep20: Rob Perez by Timmerman Report

Ep19: Chip Clark by Timmerman Report

Ep18: Ethan Perlstein by Timmerman Report

Ep17: Alice Zhang by Timmerman Report

Michael Gilman on becoming an entrepreneur.

Bruce Booth on human capital

Agios CEO David Schenkein on building a cancer R&D engine to last.

Stephane Bancel, CEO of Moderna Therapeutics, on his influences.

Abbie Celniker of Third Rock Ventures on her career, and chipping away at gender inequities in biotech.

Bob More on biotech venture capital